BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback